Tag Archives: generics

AZ's Seroquel Battle with FDA: A Mark of Desperation?

By Guest Blogger | Published: March 14, 2012
By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. Is it a mark of desperation? UK-based pharma company AstraZeneca has resorted to suing the US Food and Drug Administration in a bid to stop it from approving generic competition to Seroquel, the company’s blockbuster anti-depressant, before December 2012. The core patent for Seroquel IR expired in September [...]
Posted in Guest Blog | Also tagged , , | 3 Comments

Obama Deficit Plan Sides With PBMs Over Big Pharma

By Ben Comer | Published: September 20, 2011
Amid the flurry of cost-cutting proposals aimed at guiding the Joint Select Committee on Deficit Reduction’s (Super Committee) budgetary blade, the Obama Administration has now weighed in with a proposal to cut $248 billion from Medicare spending over ten years, and $73 billion in Medicaid and other health-related spending. The Obama plan, which would increase [...]
Posted in Regulatory, Strategy, healthcare, leadership | Also tagged , , , , | Leave a comment

Generics Win in an Express Scripts/Medco deal

By Ben Comer | Published: July 27, 2011
As a preferred generics supplier to Medco’s mail-order business, Novartis’ Sandoz division, for one, should be waiting with bated breath – and champagne at the ready – for an FTC approval of Express Scripts’ proposed $29.1 billion acquisition of Medco, which would combine two of the three largest pharmacy benefits managers (PBM), according to industry [...]
Posted in Deals, Strategy, pricing | Also tagged , , , , , | 4 Comments

Supreme Court Ruling Makes Generics More Dangerous

By Ben Comer | Published: June 23, 2011
Today’s Supreme Court ruling on Pliva v. Mensing, which held that generic drug companies are not responsible for updating drug labels in light of new safety concerns, makes taking generic drugs a riskier proposition for consumers, Justice Sonia Sotomayor wrote in her dissenting opinion. Justices Stephen Breyer, Elena Kagan and Ruth Bader Ginsburg also dissented [...]
Posted in Corporate Responsibility, Legal | Also tagged | 1 Comment

With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation

By Ben Comer | Published: May 4, 2011
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug portfolio to $7 billion in annual sales, making Teva “not only the world’s largest generics company, but also one of the world’s [...]
Posted in Deals, Strategy | Also tagged , , , | 3 Comments